AGLE:NSD-Aeglea BioTherapeutics, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 8.90

Change

-0.14 (-1.55)%

Market Cap

USD 0.40B

Volume

0.17M

Average Target Price

USD 16.00 (+79.78%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients with rare genetic and cancer diseases. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme which is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. Its preclinical pipeline products comprise ACN00177, a product candidate for the treatment of homocystinuria; AEB5100, a recombinant human enzyme that degrades plasma cystine and cysteine; AEB2109, an engineered human enzyme that targets the degradation of the amino acid methionine; and AEB3103, a product candidate. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-05-28 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

-1.13 (-0.41%)

USD72.21B 46.19 34.50
REGN Regeneron Pharmaceuticals, Inc

+34.20 (+6.29%)

USD61.35B 27.40 20.77
SGEN Seattle Genetics, Inc

-1.42 (-0.93%)

USD26.23B N/A N/A
ALXN Alexion Pharmaceuticals, Inc

+8.28 (+7.80%)

USD25.27B 9.58 8.24
INCY Incyte Corporation

+2.33 (+2.37%)

USD21.35B 47.64 35.20
MRNA Moderna, Inc

+3.36 (+6.44%)

USD20.62B N/A N/A
GMAB Genmab A/S

+1.28 (+4.31%)

USD20.17B 53.85 5.58
BMRN BioMarin Pharmaceutical Inc

-1.10 (-1.03%)

USD19.30B 164.67 98.79
ALNY Alnylam Pharmaceuticals, Inc

-0.25 (-0.19%)

USD15.31B N/A N/A
GLPG Galapagos NV

+3.68 (+1.86%)

USD12.68B 70.13 37.04

ETFs Containing AGLE

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 16.49% 65% D 83% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 16.49% 65% D 82% B-
Trailing 12 Months  
Capital Gain 39.28% 69% D+ 84% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 39.28% 69% D+ 84% B
Trailing 5 Years  
Capital Gain N/A 100% A+ 100% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A 100% A+ 100% A+
Average Annual (5 Year Horizon)  
Capital Gain N/A 100% A+ 100% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A 100% A+ 100% A+
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return 51.86% 91% A- 69% D+
Market Capitalization 0.40B 58% F 59% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 9.26 20% F 12% F
Price / Cash Flow Ratio -6.11 52% F 77% C+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -100.34% 32% F 13% F
Return on Invested Capital -126.01% 18% F 6% F
Return on Assets -52.83% 18% F 6% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 1.21 73% C 71% C-
Short Percent 0.61% 87% B+ 80% B-
Beta 2.06 24% F 13% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector